Regeneron Pharmaceuticals, Inc.
MX ˙ BMV ˙ US75886F1075
SecurityMX:REGN / Regeneron Pharmaceuticals, Inc.
InstitutionBanque Pictet & Cie Sa
Latest Disclosed Ownership9,893 shares
Latest Disclosed Value $ 7,643,728
Banque Pictet & Cie Sa reports 16.32% decrease in ownership of REGN / Regeneron Pharmaceuticals, Inc.

On April 14, 2026 - Banque Pictet & Cie Sa filed a 13F-HR form disclosing ownership of 9,893 shares of Regeneron Pharmaceuticals, Inc. (MX:REGN) valued at $7,643,728 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 16, 2026 disclosing 11,822 shares of Regeneron Pharmaceuticals, Inc.. This represents a change in shares of -16.32% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-14 2026-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 9,893 -1,929 -16.32 7,644 -16.24 0.0539
2026-01-16 2025-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 11,822 1,234 11.65 9,125 53.28 0.0535
2025-10-21 2025-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 10,588 5,115 93.46 5,953 107.21 0.0346
2025-07-16 2025-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 5,473 -664 -10.82 2,873 -26.18 0.0200
2025-04-30 2025-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 6,137 -175 -2.77 3,892 -13.43 0.0314
2025-01-30 2024-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 6,312 6,312 4,496 0.0300
2024-02-09 2023-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 0 -617 -100.00 0 -100.00
2023-11-27 2023-09-30 13F/A-1 REGENERON PHARMACEUTICALS COM 75886F107 617 -1,772 -74.17 508 -70.45 0.0060
2023-11-02 2023-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 1,545 -844 1,271 0.0139
2023-08-04 2023-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 2,389 -1,494 -38.48 1,717 -46.21 0.0151
2023-05-01 2023-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 3,883 -6,456 -62.44 3,191 -57.23 0.0309
2023-02-06 2022-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 10,339 -624 -5.69 7,459 -1.23 0.0778
2022-11-10 2022-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 10,963 1,185 12.12 7,552 30.66 0.0823
2022-08-08 2022-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 9,778 8,850 953.66 5,780 791.98 0.0572
2022-05-04 2022-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 928 0 0.00 648 10.58 0.0050
2022-02-02 2021-12-31 13F/A-1 REGENERON PHARMACEUTICALS COM 75886F107 928 0 0.00 586 4.27 0.0043
2022-02-02 2021-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 928 0 586 0.0038
2021-11-12 2021-09-30 13F/A-1 REGENERON PHARMACEUTICALS COM 75886F107 928 0 0.00 562 8.49 0.0059
2021-11-10 2021-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 928 0 562 0.0059
2021-08-12 2021-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 928 0 0.00 518 18.00 0.0058
2021-05-11 2021-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 928 0 0.00 439 -2.01 0.0056
2021-02-10 2020-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 928 0 0.00 448 -13.68 0.0061
2020-11-10 2020-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 928 0 0.00 519 -10.36 0.0078
2020-08-13 2020-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 928 0 0.00 579 27.81 0.0097
2020-04-30 2020-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 928 0 0.00 453 30.17 0.0093
2020-02-03 2019-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 928 928 348 0.0060
2019-01-31 2018-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 0 -780 -100.00 0 -100.00
2018-11-07 2018-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 780 -583 -42.77 315 -32.98 0.0058
2018-08-09 2018-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 1,363 -5,964 -81.40 470 -81.37 0.0092
2018-05-09 2018-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 7,327 -400 -5.18 2,523 -13.15 0.0531
2018-02-09 2017-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 7,727 -1,318 -14.57 2,905 -28.18 0.0580
2017-11-07 2017-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 9,045 1,455 19.17 4,045 8.50 0.0916
2017-08-09 2017-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 7,590 7,590 3,728 0.0887
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.